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Abstract (236/250) 47 
Objective: Clinically, anorexia nervosa (AN) presents with altered body composition. We 48 
quantified these alterations and evaluated their relationships with metabolites and hormones 49 
in AN patients longitudinally. 50 
Method: In accordance with PRISMA guidelines, we conducted 88 meta-analyses on 60 51 
samples published 1996-2018, comparing up to 2,294 pre-treatment, post-treatment, and 52 
weight-recovered AN patients with up to 1,848 controls. Primary outcomes were fat mass, 53 
fat-free mass, body fat percentage, and their regional distribution. Secondary outcomes were 54 
bone mineral density, metabolites, and hormones. Meta-regressions examined relationships 55 
among those measures and moderators.  56 
Results: Pre-treatment AN patients evidenced 50% lower fat mass (MD: -9.05 kg, CI 95%: -57 
10.02, -8.07, Q = 9.33 x 10-73) and 4.96 kg (CI 95%: -5.84, -4.07, Q = 9.30 x 10-27) lower fat-58 
free mass, with fat mass preferentially stored in the trunk region during early weight 59 
restoration (4.2%, CI 95%: -2.1, -6.2, Q = 2.30 x 10-4). While the majority of traits returned 60 
to levels seen in healthy controls after weight restoration, fat-free mass (MD: -1.82 kg, CI 61 
95%: -2.57, -1.08, Q = 5.41 x 10-6) and bone mineral density (MD: -0.10 kg, CI 95%: -0.18, -62 
0.03, Q = 0.01) remained significantly altered.  63 
Discussion: Body composition is markedly altered in AN, warranting research into these 64 
phenotypes as clinical risk or relapse predictors. Notably, the long term altered levels of fat-65 
free mass and bone mineral density suggest that these parameters should be investigated as 66 
potential AN trait markers.  67 
  68 
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Introduction 69 
Anorexia nervosa (AN) has one of the highest mortality rates of all psychiatric 70 
disorders (Chesney, Goodwin, & Fazel, 2014). Clinical observations show altered body 71 
composition (El Ghoch, Calugi, Lamburghini, & Dalle Grave, 2014; Solmi et al., 2016) 72 
accompanied by elevated cholesterol (Hussain et al., in press) and greater insulin sensitivity 73 
(Ilyas et al., 2018). However, conclusions are limited by small sample sizes and consequent 74 
mixed findings. 75 
Molecular genetic studies have revealed that individuals with AN carry genetic 76 
variants that increase their liability to AN and concurrently predispose to lower body fat 77 
percentage, lower fasting insulin, and higher high-density lipoprotein (HDL) cholesterol 78 
concentrations, suggesting that metabolic factors may play an etiological role (Duncan et al., 79 
2017; Watson et al., 2018). Additionally, longitudinal investigations of a British birth cohort 80 
showed that girls who develop AN later in life are already underweight at the age of 4 years 81 
when compared to healthy children (Yilmaz, Gottfredson, Zerwas, Bulik, & Micali, in press), 82 
adding evidence for a developmental component.  83 
A systematic review showed that adolescents and adults differently lose fat tissue 84 
when affected by AN, with adolescents losing more central fat tissue and adults more 85 
peripheral fat tissue. During weight recovery, individuals with AN show emergent central 86 
adiposity which typically attenuates over time (El Ghoch, Calugi, et al., 2014). These clinical 87 
and genetic findings encourage the meta-analytic reassessment of the role of body 88 
composition traits, such as fat mass and fat-free mass, their regional distribution, and their 89 
changes associated with weight restoration and long-term weight recovery in AN. 90 
The goals of these meta-analyses were to (1) replicate findings from the systematic 91 
review on fat mass; (2) extend the observations by quantifying them; (3) include fat-free mass 92 
and (4) bone mineral content and density; (5) investigate their associations with each other; 93 
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and (6) if possible, relate findings to secondary outcomes, such as metabolic and hormonal 94 
parameters. This analytical approach is aimed at understanding the potential associations 95 
between these factors that are known to be physiologically interrelated. A thorough and 96 
rigorous examination of body composition and related laboratory parameters in individuals 97 
with AN could elucidate some of the physiological changes associated with this serious 98 
disorder, which could lead to more effective medical management, monitoring, and treatment 99 
approaches. 100 
 101 
Methods 102 
Search strategy 103 
Our meta-analysis was conducted according to PRISMA guidelines (Moher, Liberati, 104 
Tetzlaff, Altman, & PRISMA Group, 2009) and pre-registered (PROSPERO 2018 105 
CRD42018105338) with no changes to the protocol. We conducted a literature search from 106 
15.06.2018 until 01.07.2018 using the electronic database PubMed with a time limitation 107 
starting with articles published after 01.01.1994––marking the introduction of the Diagnostic 108 
and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV; American Psychiatric 109 
Association, 2013)––until 31.06.2018. We used key search terms including "anorexia 110 
nervosa" AND ("body composition" OR "body fat" OR "fat mass" OR "body fat percentage" 111 
OR DXA OR BIA OR "fat free mass" OR "lean mass"). The search was repeated by co-112 
authors to avoid selection bias. Furthermore, we screened the references of published articles 113 
and reviews. Our search results including the selection process are presented in Supporting 114 
Information Figure S1 according to PRISMA guidelines. 115 
 116 
  117 
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Selection criteria 118 
Our inclusion criteria were as follows: 119 
a. Studies investigating humans only 120 
b. Any age group 121 
c. No sample overlap 122 
d. Observational cross-sectional or longitudinal studies or randomised-controlled trials 123 
e. Clinical diagnoses of AN according to the Diagnostic and Statistical Manual of 124 
Mental Disorders (DSM) IV, 5, or their revisions (American Psychiatric Association, 125 
2013), or International Classification of Diseases version 10 (ICD-10) (World Health 126 
Organization, 1992) 127 
f. Investigation of body composition by dual-energy X-ray absorptiometry (DXA) 128 
(Bredella et al., 2010, 2013), bioelectrical impedance analysis (BIA) (Bonaccorsi et 129 
al., 2012; Mattar et al., 2011), dual photon absorptiometry (DPA), or magnetic 130 
resonance imaging (MRI) (Mayer et al., 2005). 131 
g. Published after 01.01.1994 (the year that DSM-IV was introduced) 132 
h. The study includes a control group or comparison group 133 
i. Publications in any language which could be translated by the research team: English, 134 
German, Swedish, Danish, Spanish 135 
 136 
In case of multiple publications deriving from the same study population, we selected 137 
the articles reporting either the largest or the most recent data set. In case of conflict between 138 
these two criteria, large sample size was prioritized.  139 
 140 
  141 
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Data extraction 142 
We extracted the following information from every identified study using a 143 
standardised data extraction sheet: 144 
a. Author, publication year 145 
b. Country 146 
c. Sample sizes including gender and age 147 
d. Setting: inpatient or outpatient 148 
e. Original longitudinal or cross-sectional design 149 
f. Follow-up period if longitudinal 150 
g. Diagnostic criteria: DSM-IV, DSM-IV-TR, DSM-5, or ICD-10 151 
h. Participant screening and exclusion criteria 152 
i. Number of cases: AN pre-treatment, post-treatment (ANpost), recovered from AN 153 
(ANrec) 154 
j. Subtype of AN: restricting (R), binge-eating/purging (BP) 155 
k. Number of controls (CO) 156 
l. Primary outcome variables of body composition: fat mass (FM), fat-free mass (FFM), 157 
body fat percentage (BF%), and their regional distribution 158 
m. Secondary outcome variables, which were reported by at least four studies additional 159 
to primary outcomes: bone mineral density (BMD), glucose, insulin, ghrelin, 160 
adiponectin, leptin, insulin-like growth factor (IGF-1), estradiol, testosterone, cortisol, 161 
thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4) 162 
n. Covariates used in original analysis  163 
o. Fasting and fasting duration  164 
p. Blood sample: serum, plasma, or unspecified  165 
q. Medication and contraceptives 166 
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r. Psychological and additional treatments 167 
s. Outcome was a secondary or primary outcome in the original study 168 
t. Duration of illness 169 
u. Age at diagnosis/onset 170 
v. Age at menarche 171 
w. Percentage of AN cases with amenorrhea and duration of amenorrhea 172 
 173 
Quality of study assessment (Newcastle-Ottawa Scale) 174 
We used the Newcastle-Ottawa Scale (NOS) to assess the quality of studies (Wells et 175 
al., 2009). For the observational studies, low quality was defined as Newcastle–Ottawa Scale 176 
score ≤8.0 and high quality as score >8.0 (maximum score 9). 177 
 178 
Meta-analysis 179 
Inverse variance-weighted meta-analyses were conducted using the statistical package 180 
‘meta’ and ‘metafor’ in the open source software R v3.5.1 (r-project.org). We used additional 181 
formulas to calculate missing values (Hozo, Djulbegovic, & Hozo, 2005; Luo, Wan, Liu, & 182 
Tong, 2018; Wan, Wang, Liu, & Tong, 2014). Mean differences (MDs) between clinical and 183 
control groups were the effect sizes. A random-effects model, which assumes that the 184 
heterogeneity in the differences between clinical and control groups is due to both within-185 
study and between-study variation, was used as we anticipated differences in procedures and 186 
study populations between studies. We used a restricted maximum-likelihood estimator 187 
(REML) to calculate the heterogeneity. For the analysis of subtypes, post-treatment, and 188 
weight-recovered AN patients, the control groups from the acutely-ill/pre-treatment analysis 189 
were reused because (1) control groups were not measured repeatedly; and (2) none of the 190 
studies had separate control groups for each subtype analysis. Although some studies 191 
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included covariates in their statistical analysis (Bratland-Sanda et al., 2010; Bredella et al., 192 
2008; Dellava, Policastro, & Hoffman, 2009; DiVasta et al., 2007; Fernández-Soto, 193 
González-Jiménez, Chamorro-Fernández, & Leyva-Martínez, 2013; Haas et al., 2005; 194 
Karlsson, Weigall, Duan, & Seeman, 2000; Kosmiski, Schmiege, Mascolo, Gaudiani, & 195 
Mehler, 2014; Maïmoun et al., 2018; Nakahara et al., 2007; Schneider et al., 1998), we only 196 
used raw values without including study-specific covariates to increase comparability across 197 
individual studies. Weight recovery was defined in accordance with DSM-IV and DSM-5 198 
criteria with BMI >18.5 kg/m2 or >90% ideal body weight (IBW). To correct our primary 199 
analysis for multiple testing, False Discovery Rate-adjusted Q values were calculated 200 
(Benjamini & Hochberg, 1995). 201 
 202 
Publication bias or small study effects 203 
Meta-analyses should diminish both bias and uncertainty of the overall estimate; 204 
however, this is not always the case as published studies may represent a biased selection of 205 
evidence (Nieminen, Rucker, Miettunen, Carpenter, & Schumacher, 2007). To detect 206 
publication bias, we inspected funnel plots visually (Egger, Smith, Schneider, & Minder, 207 
1997) and quantified their asymmetry using a weighted linear regression by Thompson and 208 
Sharp––which allows for between-study heterogeneity (Thompson & Sharp, 1999). The 209 
significance of this test (p < 0.05) indicates asymmetric funnel plots and suggests publication 210 
bias or small study effects. In this case, we fitted a Copas selection model to adjust our meta-211 
analysis for these effects. 212 
 213 
  214 
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Copas selection model 215 
The Copas selection model to correct for potential selection bias comprises: (1) a 216 
model for the meta-analyzed effect; and (2) a model estimating the probability that study k is 217 
selected for publication. The correlation parameter ⍴ between these two components indicates 218 
the extent of publication bias with larger correlations suggesting more extreme effects have 219 
been selected for publication (Copas, 1999; Copas & Shi, 2000, 2001). We used the R 220 
package ‘metasens’ which fits the Copas selection model repeatedly over a grid of tuning 221 
parameters 𝛾0 and 𝛾1 and creates a standardised output: a) a funnel plot, b) a contour plot, c) a 222 
treatment effect plot, and d) a p value plot.  223 
 224 
Meta-regression and stratified subgroup analysis 225 
We detected extensive heterogeneity across the studies (Table 1). The heterogeneity 226 
observed in a meta-analysis can be partially systematic and related to clinical study-level 227 
variables (i.e., moderators), such as age or AN subtype. In secondary analyses, potential 228 
moderators were therefore explored in stratified subgroup analyses, such as AN subtype, or 229 
via meta-regression analyses, including mean age, the time period of follow-up for 230 
longitudinal studies, age at diagnosis, age at menarche, age at amenorrhea, duration of illness, 231 
percentage of amenorrhea in AN patients, percentage of medicated AN patients, percentage 232 
of individuals taking contraceptives, body composition measurement method, blood sample 233 
type, body composition parameters and their differences between cases and controls. Mixed 234 
effects models allow for within-study and between-study variation and were therefore the 235 
most appropriate model indicated by the large heterogeneity estimates detected in our 236 
primary meta-analyses. We used a restricted maximum-likelihood (REML) estimator to 237 
calculate the heterogeneity included in the R package ‘meta’. 238 
  239 
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Results 240 
Results of the search and selection of studies 241 
A total of 510 papers published between 1996 and 2018 were identified by our search 242 
terms, and 450 of them were excluded. No paper published 1994-1996 fulfilled the inclusion 243 
criteria and the most common reasons for exclusion were: (1) no control group (n = 137); (2) 244 
sample overlap (n = 65); and (3) no main outcome reported (i.e., body composition; n = 45). 245 
Detailed exclusion process is presented in Supporting Information Figure S1. Sixty published 246 
articles were included in our analysis (Agüera et al., 2015; Bachmann et al., 2014; 247 
Benninghoven, Raykowski, Solzbacher, Kunzendorf, & Jantschek, 2007; Bratland-Sanda et 248 
al., 2010; Bredella et al., 2012, 2008; Chudecka & Lubkowska, 2016; de Alvaro et al., 2007; 249 
Dellava et al., 2009; Delporte, Brichard, Hermans, Beguin, & Lambert, 2003; de Mateo 250 
Silleras et al., 2013; Diamanti et al., 2007; DiVasta et al., 2007, 2011; Dostálová, Sedlácková, 251 
Papezová, Nedvídková, & Haluzík, 2009; El Ghoch et al., 2012, 2015; El Ghoch, Calugi, 252 
Milanese, Bazzani, & Dalle Grave, 2017; El Ghoch, Milanese, et al., 2014; El Ghoch, 253 
Pourhassan, et al., 2017; Estour et al., 2017; Faje et al., 2014; Fazeli et al., 2010; Fernández-254 
Soto et al., 2013; Galusca et al., 2015; Germain et al., 2010, 2007, 2016; Gniuli, Liverani, 255 
Capristo, Greco, & Mingrone, 2001; Grinspoon et al., 1996, 2001; Guo, Jiang, Liao, Liu, & 256 
He, 2013; Haas et al., 2018, 2005; Iacopino et al., 2003; Karczewska-Kupczewska et al., 257 
2010; Karlsson et al., 2000; Kaválková et al., 2012; Kerruish et al., 2002; Kirchengast & 258 
Huber, 2004; Konstantynowicz et al., 2011; Kosmiski et al., 2014; Maïmoun et al., 2018; 259 
Mayer et al., 2009, 2005; Mika, Herpertz-Dahlmann, Heer, & Holtkamp, 2004; Misra et al., 260 
2013; Moreno, Djeddi, & Jaffrin, 2008; Mörkl et al., 2017; Nakahara et al., 2007; Nakai, 261 
Hamagaki, Takagi, Taniguchi, & Kurimoto, 1999; Prioletta et al., 2011; Rigaud, Boulier, 262 
Tallonneau, Brindisi, & Rozen, 2010; Scalfi, Marra, Caldara, Silvestri, & Contaldo, 1999; 263 
Scalfi et al., 2002; Schneider et al., 1998; Singhal et al., 2018; Tagami et al., 2004; Tanaka et 264 
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al., 2003; Weinbrenner et al., 2004), and we became aware of no additional unpublished 265 
samples after contacting study authors for additional or missing data (Supporting Information 266 
Table S1). The majority of studies focused on female cases and controls that were sampled 267 
consecutively in only 21 of 60 studies (Supporting Information Table S2) and aged between 268 
14.2 and 31.0 years (Supporting Information Figure S2). As such, two studies investigating 269 
male AN cases were excluded from the qualitative synthesis but are discussed briefly (El 270 
Ghoch, Calugi, et al., 2017; Misra et al., 2013). Three studies originated from Australasia, 37 271 
from Europe, 15 from North America, and five from Asia. Only 13 studies used the same 272 
method of ascertainment for cases and controls (Supporting Information Table S2). Twenty-273 
eight studies investigated inpatients, eight outpatients, two a mixture of both, and 22 studies 274 
did not specify the recruitment or patient setting. All studies comprised collection of blood 275 
samples after a fasting period, whereas only six studies specified the fasting period (Bredella 276 
et al., 2012; DiVasta et al., 2011; Dostálová et al., 2009; Estour et al., 2017; Kaválková et al., 277 
2012; Prioletta et al., 2011). One study did not specify whether analyses were performed 278 
using plasma or serum blood (Weinbrenner et al., 2004). Seventeen studies sampled regular 279 
menstruating participants during the follicular phase of their cycle (de Alvaro et al., 2007; 280 
Dostálová et al., 2009; Estour et al., 2017; Galusca et al., 2015; Germain et al., 2010, 2007, 281 
2016; Kaválková et al., 2012; Kirchengast & Huber, 2004; Mayer et al., 2005; Nakai et al., 282 
1999; Prioletta et al., 2011; Weinbrenner et al., 2004), whereas 13 studies did not provide 283 
details about cycle phase (Bachmann et al., 2014; Bredella et al., 2012; Delporte et al., 2003; 284 
DiVasta et al., 2011; Fazeli et al., 2010; Fernández-Soto et al., 2013; Germain et al., 2010; 285 
Gniuli et al., 2001; Grinspoon et al., 1996; Guo et al., 2013; Haas et al., 2005; Karczewska-286 
Kupczewska et al., 2010; Maïmoun et al., 2018; Mörkl et al., 2017; Nakahara et al., 2007; 287 
Rigaud et al., 2010; Tagami et al., 2004; Tanaka et al., 2003). However, studies were retained 288 
to achieve the largest possible sample size, and––depending on data availability––meta-289 
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regressions were fitted to investigate study characteristics as possible moderators. Originally, 290 
39 studies were cross-sectional and 21 longitudinal (Supporting Information Table S1). 291 
However, three of the longitudinal studies were analysed cross-sectional in our meta-analysis 292 
due to missing data. No control group was repeatedly measured in any of the longitudinal 293 
studies. 294 
 295 
Characteristics of the included studies 296 
We performed four meta-analyses: 1) comparing 2,697 pre-treatment/acutely-ill AN 297 
patients with 2,251 healthy controls; 2) comparing 722 post-treatment AN patients with 809 298 
controls; 3) estimating the change in AN patients (n = 722) from pre- to post-treatment; and 299 
4) comparing 398 weight-recovered individuals with AN with 660 healthy controls including 300 
samples with long-term follow-up. The pre-treatment AN group comprised 229 individuals 301 
suffering from the binge-eating/purging and 681 from the restricting subtype. The shortest 302 
follow-up period was 5.14 weeks, and the longest was 2 years (Supporting Information Table 303 
S1). Nineteen studies used BIA to assess body composition, 38 used DXA, and only three 304 
utilized MRI––considered to be the gold standard. Thirty of the 60 studies investigated body 305 
composition as a primary outcome, whereas it was a secondary outcome in the remaining 306 
studies. The percentage of AN patients with amenorrhea ranged from 43 to 100%, with ten 307 
studies not providing information on menstrual status (Agüera et al., 2015; Bachmann et al., 308 
2014; Bredella et al., 2012; de Mateo Silleras et al., 2013; El Ghoch et al., 2012; Gniuli et al., 309 
2001; Iacopino et al., 2003; Kirchengast & Huber, 2004; Schneider et al., 1998; Tagami et al., 310 
2004; Tanaka et al., 2003). Thirty-five of 60 studies did not provide information on the 311 
medication status of AN patients, and 30 did not indicate whether oral contraceptives were 312 
used. In AN cases, the duration of illness was on average 52.59 months (SD = 29.08), the 313 
duration of amenorrhea 22.99 months (SD = 18.27), and the age at diagnosis 17.45 years (SD 314 
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= 3.01). Cases and controls were well matched for age (Supporting Information Figure S2) 315 
and, notably, we did not observe a difference in age at menarche (Supporting Information 316 
Figure S3) or height (Supporting Information Figure S6) between AN cases and controls. 317 
 318 
Data and analyses results of meta-analyses and meta-regressions 319 
Our results from the 88 meta-analyses show that a wide range of alterations in several 320 
key body composition and biochemical measures exist in AN cases compared with healthy 321 
controls (Figure 1/Supporting Information Figure S4). For 95% confidence intervals and Q 322 
values, heterogeneity estimates, and adjusted estimates due to estimated publication bias, see 323 
Table 1. Detailed forest plots showing each of the 88 meta-analyses are presented as 324 
Supporting Information Figures S5-92. No differences between restricting and binge-325 
eating/purging subtype of AN were detected in our meta-analysis prior to treatment except 326 
for total body water (Supporting Information Table S3). Between-study heterogeneity (I2) 327 
was observed in 62 meta-analyses and ranged from 52 to 99%, confirming our choice of a 328 
random-effects model. To investigate moderators implicated in heterogeneity, we performed 329 
398 meta-regressions (Supporting Information Table S4-7). Eight meta-analyses showed 330 
funnel plot asymmetry, indicating small study effects. Therefore, we fitted Copas models to 331 
adjust for those effects and estimate the probable number of unpublished studies (Table 1 and 332 
Supporting Information Figure S93-100). 333 
 334 
  335 
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Primary outcomes: body composition 336 
Anthropometrics 337 
On average, pre-treatment AN cases had a 15.61 kg (CI 95%: -16.98, -14.24, Q = 7.26 338 
x 10-109) lower body weight and were 0.01 m (CI 95%: -0.01, 0.00, Q = 0.03) shorter than 339 
healthy controls given their age (βmetareg = -0.002, p = 0.04 ;Supporting Information Table 340 
S4). After treatment, AN patients still weighed 4.92 kg (CI 95%: -8.03, -1.81, Q = 1.92 x 10-341 
3) less than healthy controls.  342 
Correspondingly, the pre-treatment BMI difference between AN cases and controls 343 
was -5.88 kg/m2 (CI 95%: -6.31, -5.46, Q = 9.06 x 10-158), which reduced to -2.10 kg/m2 (CI 344 
95%: -2.53, -1.67, padjCopas < 1.00 x 10
-4) after treatment as most patients gained on average 345 
9.93 kg (CI 95%: 8.17, 11.68, Q = 2.11 x 10-27) during treatment. Post-treatment BMI was 346 
primarily accounted for by gains in fat mass (βmetareg = 0.81, p = 7.03 x 10-7) but not through 347 
fat-free mass (Supporting Information Table S5). After weight recovery, no statistically 348 
significant mean difference in BMI between AN cases and controls was detected. 349 
 350 
Fat mass  351 
The pre-treatment body composition of individuals with AN was significantly altered. 352 
Compared with healthy controls, AN cases had 9.05 kg (CI 95%: -10.02, -8.07, Q = 9.33 x 353 
10-73) lower fat mass, corresponding to a 13.9% (CI 95%: -15.2, -12.6, Q = 9.59 x 10-99) 354 
lower complete body mass. This suggests that body fat was on average 50% lower than in 355 
healthy controls. Body fat percentage (βmetareg = -134.53, p = 0.01) and absolute fat mass 356 
(βmetareg = -49.26, p = 1.65 x 10-4) were associated with whole body bone mineral density of 357 
AN patients. Absolute fat mass was also associated with mean age at diagnosis (βmetareg = -358 
1.21, p = 2.42 x 10-4; Supporting Information Table S4).  359 
 16 
 
After treatment, AN patients had a 2.37 kg (CI 95%: -3.75, -0.98, Q = 0.002) lower 360 
fat mass which corresponded to 2.5% (CI 95%: -4.3, -0.7, padjCopas = 0.006) less total body 361 
mass compared with healthy controls. AN patients gained 6.39 kg (CI 95%: 5.13, 7.65, Q = 362 
3.07 x 10-22) fat mass following treatment which corresponded to 10.4% (CI 95%: 7.96, 363 
12.87, Q = 6.25 x 10-16) of total body mass. Post-treatment fat mass (βmetareg = -0.23, p = 0.01; 364 
Supporting Information Table S5) and gain in fat mass during treatment (βmetareg = -0.20, p = 365 
0.02; Supporting Information Table S6) were negatively associated with the presence of 366 
amenorrhea. Following weight recovery, these values fully returned to levels seen in healthy 367 
controls.  368 
Specifically, compared with healthy controls, AN patients had 3.51 kg (CI 95%: -369 
4.58, -2.43, Q = 8.07 x 10-10) less trunk fat mass prior to treatment. In relative terms, 370 
however, AN patients had lower extremity body fat with 5.4% (CI 95%: -8.38, -2.43, Q = 371 
8.23 x 10-4) less total body mass. The presence of amenorrhea was significantly associated 372 
with lower extremity fat mass (βmetareg = 0.31, p = 0.04; Supporting Information Table S4). 373 
After treatment, AN patients showed a higher trunk body fat percentage than controls 374 
at 12.0% (CI 95%: 9.5, 14.4, padjCopas < 1.00 x 10
-4) of total body mass. However, this finding 375 
was strongly influenced by publication bias with an estimated 52 unpublished studies. These 376 
results on body composition were not influenced by height as cases and controls showed no 377 
meaningful difference (i.e., 1 cm pre-treatment) or by age as meta-regressions were non-378 
significant (Supporting Information Tables S4-7). 379 
 380 
  381 
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Fat-free mass 382 
Overall, the fat-free mass in AN patients was 4.96 kg (CI 95%: -5.84, -4.07, Q = 9.30 383 
x 10-27) lower pre-treatment than in controls, corresponding to 12.3% (CI 95%: 8.1, 16.5, Q = 384 
3.07 x 10-8) higher proportion of total body mass. During treatment, AN patients gained 2.98 385 
kg (CI 95%: 1.74, 4.22, Q = 6.89 x 10-6) fat-free mass, resulting in 1.82 kg (CI 95%: -2.57, -386 
1.08, Q = 5.41 x 10-6) lower fat-free mass compared to controls. Yet, weight-recovered 387 
individuals with AN still showed 1.27 kg (CI 95%: -1.79, -0.75, Q = 5.49 x 10-6) lower fat-388 
free mass than controls.  389 
More specifically, pre-treatment fat-free mass of the extremities was 1.5% (CI 95%: -390 
2.0, -1.0, Q = 8.84 x 10-9) less of total body mass. After treatment, no marked regional 391 
differences in fat-free mass were observed in AN patients. However, weight-recovered 392 
individuals with AN had 0.9% (CI 95%: -1.3, -0.5, Q = 6.30 x 10-5) lower trunk fat-free mass 393 
of total body mass than controls.  394 
 395 
Before treatment, we observed a 393.95 kcal/day (CI 95%: -531.04, -256.86, Q = 6.27 396 
x 10-8) lower resting energy expenditure and 4.65 L (CI 95%: -6.21, -3.10, Q = 1.78 x 10-8) 397 
less total body water in AN patients which persisted with 3.71 L (CI 95%: -7.07, -0.36, Q = 398 
0.05) after treatment. Both were measured by BIA. However, resting energy expenditure was 399 
not corrected for fat-free mass or body mass in the original studies, limiting its 400 
interpretability. The association between total body water and fat-free mass could not be 401 
investigated as too few studies reported both outcomes concurrently. 402 
Before treatment, only the amount of total body water was significantly different 403 
between individuals (psubgroup = 0.004) suffering from the restricting (-5.21 L, CI 95%: -9.06, 404 
-1.36, pR = 8.04 x 10
-3, k = 3) or the binge-eating/purging subtype (-11.1 L, CI 95%: -12.04, -405 
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10.16, pBP = 5.06 x 10
-119, k = 1; Supporting Information Table S3). However, this finding 406 
was limited by only one study investigating the binge-eating/purging subtype.  407 
 408 
Secondary outcome: bone mineral measures 409 
Bone mineral content and density 410 
Compared with healthy controls, whole body bone mineral content in individuals with 411 
AN was 0.16 kg (CI 95%: -0.19, -0.12, Q = 2.73 x 10-20) lower pre-treatment and 0.09 kg (CI 412 
95%: -0.13, -0.05, Q = 1.63 x 10-5) lower post-treatment. Weight-restored individuals with 413 
AN showed 0.10 kg (CI 95%: -0.18, -0.03, Q = 0.01) lower whole body bone mineral content 414 
compared to controls as they gained on average 0.05 kg (CI 95%: 0.02, 0.09, Q = 0.01) 415 
during treatment. The interpretability of these estimates is limited due to the insufficient 416 
follow-up time after weight recovery, exceeding six months in only two studies (Dellava et 417 
al., 2009; Karlsson et al., 2000). The pre-treatment whole body bone mineral content was 418 
associated with fat-free mass (βmetareg = 0.02, p = 0.02) and fat mass (βmetareg = 0.05, p = 0.02), 419 
as well as the difference in fat mass between AN patients and controls (βmetareg = 0.04, p = 420 
0.002; Supporting Information Table S4). Accordingly, whole body pre-treatment bone 421 
mineral density was 0.03 g/cm2 (CI 95%: -0.07, -0.00, padjCopas = 0.02) lower in AN, but our 422 
analysis showed a density comparable with healthy controls post-treatment. However, only 423 
two studies with 74 AN cases could be included in this analysis.  424 
Before treatment, AN patients exhibited lower bone mineral density in several 425 
regions, including hip, lumbar spine, and femoral neck, with a few being likely to persist after 426 
weight recovery. These findings were associated with duration of illness, the age of AN 427 
cases, and differences in fat mass between cases and controls (Supporting Information: 428 
Secondary outcomes: detailed bone mineral measures and Table S4). Cases and controls in 429 
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our meta-analyses were age- and height-matched (Supporting Information Figure S2 & S6), 430 
therefore, these variables are unlikely to be associated with these results. 431 
 432 
Secondary outcomes: metabolites and hormones 433 
Exploratory results showed that fasting insulin and glucose concentrations were lower in AN 434 
patients compared with controls but not associated with fat or fat-free mass while lower leptin 435 
was associated with fat mass pre-treatment. After treatment, these measures returned to 436 
concentrations seen in healthy controls. Before treatment, thyroid hormones, cortisol, and 437 
IGF-1 were lower in AN patients and all three measures were associated with fat mass 438 
whereas higher cortisol in AN patients was associated with fat-free mass. For detailed results 439 
see Supporting Information: Secondary outcomes: metabolites and hormones. 440 
 441 
Methodological moderators 442 
 We observed strong between-study heterogeneity (Table 1). To investigate how 443 
differences in study design, samples, and measurement methods may influence the primary 444 
and secondary outcomes, we performed an additional set of meta-regressions (Supporting 445 
Information Tables S4-7). The method of body composition measurement was associated 446 
with pre-treatment body fat percentage (βDXA = 3.34, p = 0.008), fat-free mass (βIsotope Dilution = 447 
-6.18, p = 0.009), and fat-free mass percentage (βDXA = -8.28, p = 0.01) and post-treatment 448 
body fat percentage (βDXA = 6.39, p = 0.005) . Furthermore, femoral neck bone mineral 449 
density (βOutpatient = -0.12, p = 7.65 x 10-4) significantly differed between inpatients and 450 
outpatients. 451 
 452 
  453 
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Discussion 454 
Our primary meta-analyses showed marked alterations in body composition traits in 455 
patients with AN before and after treatment. Before treatment, all three major body 456 
compartments—fat, fat-free, and bone mass—showed significant reductions that were only 457 
partially restored after treatment. Our meta-analysis estimated  ~50% lower body fat in AN 458 
patients which was mirrored by leptin concentrations (Perry & Shulman, 2018), both of 459 
which recovered with treatment. Significant differences were observed in body fat 460 
distribution post-treatment as body fat was primarily stored in the trunk. This distribution 461 
pattern may be due to increased insulin sensitivity observed in AN patients (Ilyas et al., 2018) 462 
potentially similar to observations in healthy individuals after short-term overfeeding 463 
(McLaughlin et al., 2016). We did not detect meaningful or statistically significant 464 
differences in body fat distribution in weight-restored patients, indicating potential 465 
redistribution occurring over longer term follow-up. 466 
A new finding from our meta-analysis is that lower fat mass in AN was correlated 467 
with significantly low bone mineral content and density across the whole body. We speculate 468 
that the hormonal cross-talk between fat and bone tissue may be influencing this association 469 
(El Ghoch et al., 2016; Hawkes & Mostoufi-Moab, 2018), potentially mediated through 470 
greater bone marrow adipose tissue observed in AN (Fazeli & Klibanski, 2018; Suchacki & 471 
Cawthorn, 2018). Whole body bone mineral content remained low in weight-recovered 472 
individuals with AN. However, as only two studies followed patients for longer than six 473 
months (Dellava et al., 2009; Karlsson et al., 2000), the length of follow-up was insufficient 474 
to draw firm conclusions because bone mineral mass is slow to normalize. Future studies 475 
should be designed to capture long term changes. In men with AN, it has been reported that 476 
short-term weight restoration may normalize body composition patterns but could also lead to 477 
central adiposity (El Ghoch, Calugi, et al., 2017). However, sample sizes of reports of males 478 
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are very small. Additionally, in our analysis alterations in bone mineral mass did not affect 479 
the height of individuals with AN.  480 
Another new finding in our meta-analysis is that we observed a 5 kg lower fat-free 481 
mass in AN patients which remained lower even after treatment and in weight-recovered AN 482 
patients, indicating that current treatment regimes may insufficiently target fat-free mass. 483 
Future studies should also assess muscle mass to identify the components of fat-free mass 484 
that are most associated with this reduction. 485 
Our secondary outcomes––associations between detailed body composition and 486 
laboratory parameters in AN––were difficult to assess as only a few published studies 487 
reported both outcomes consistently. Most biochemical alterations were within the range of 488 
normal reference values. However, serious alterations can occur in certain individuals with 489 
AN that warrant vigilance by clinicians. 490 
Overall, the meta-analyzed study sample was highly selected and biased as it 491 
comprised mostly European females aged between 14 and 31 years, emphasising the urgent 492 
need for studies including diverse ancestries, such as Asia, South and Central America, and 493 
Africa. Females and males differ in body composition and metabolic characteristics 494 
(Karastergiou & Fried, 2017; Link & Reue, 2017), underscoring the need for more studies on 495 
males with AN. Our study selection was limited by lack of control groups and underreported 496 
extensive sample overlap. Moreover, control groups were only measured at baseline in all 497 
longitudinal studies, failing to account for age- and growth-related variation, potentially 498 
inflating estimates. Furthermore, no clear-cut and consistent definition of recovery from AN 499 
was used across studies, contributing to heterogeneity (Murray, Loeb, & Le Grange, 2018). 500 
This underscores the necessity of developing standard definitions of remission and recovery 501 
in the eating disorders field (Bardone-Cone, Hunt, & Watson, 2018). 502 
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Methodologically, we observed effects of either BIA or DXA on the measurement of 503 
body composition in AN, questioning the comparability of the two methods. Larger, 504 
longitudinal validation studies comparing both methods with whole body MRI in eating 505 
disorders should be conducted. Additional factors influencing body composition and 506 
biochemical measures, such as menstrual cycle, diurnal changes, fasting, and pre-analytical 507 
procedures are summarised in Table 2 and should be carefully assessed in future studies 508 
(Hernandes, Barbas, & Dudzik, 2017). 509 
Most importantly, blood is comprised of approximately 3,500 highly correlated and 510 
interacting proteins (hupo.org) (Schwenk et al., 2017) and 4,600 metabolites 511 
(serummetabolome.ca) (Psychogios et al., 2011), therefore, the measurement of single 512 
proteins, hormones or metabolites is ill-advised. Metabolomics, proteomics, and lipidomics 513 
can capture large amounts of information at adequate statistical power when used in large 514 
samples (Hernandes et al., 2017). Additionally, large epidemiological databases that have 515 
measured biomarkers in childhood, such as the Avon Longitudinal Study of Parents and 516 
Children (ALSPAC; Golding, Pembrey, Jones, & ALSPAC Study Team, 2001) and 517 
Generation R (Kooijman et al., 2016), should be harnessed to determine whether those who 518 
go on to develop AN show evidence for premorbid differences in body composition and 519 
biochemical parameters as has been observed for BMI by Yilmaz et al. (Yilmaz et al., in 520 
press). 521 
 522 
  523 
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Conclusions 524 
Detailed measurement of body composition with simple methods, such as BIA or 525 
DXA, that offers additional information on bone tissue, may help refine our understanding of 526 
the nature of AN and its diagnosis. Our meta-analyses showed that all body compartments 527 
were markedly altered in AN. Individuals with AN presented with 50% lower fat mass and 528 
prolonged recovery periods for fat-free mass and bone mineral content. The core implication 529 
of body composition differences are alterations in metabolism, growth, and development. 530 
While results must be interpreted with caution given small samples, we found evidence 531 
indicating alterations in fasting insulin, thyroid, sex, and stress hormones in AN which 532 
appeared to partially normalize with weight gain and recovery. Large birth cohorts that 533 
collected information on eating disorders along with metabolomic information offer a rich 534 
and exciting opportunity for prospective investigations that add to our understanding of body 535 
composition and metabolic mechanisms in risk and maintenance of eating disorders. 536 
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Table 2 Minimum requirement of variables that should be assessed, reported, and included in 867 
statistical analyses of case-control studies examining anorexia nervosa or other eating 868 
disorders to facilitate reproducibility, meta-analysis, and -regression [adapted from, 111] 869 
Sampling Sample characteristics 
Cases and controls 
● Underlying population: community, 
hospital 
● Consecutive sample or selection 
● If consecutive, attrition & reasons 
● Diagnosis & ascertainment 
● Diagnostic schema 
● Independent validation 
Controls 
● Repeated measurement 
● Exclusion of current and history of 
diagnosis (i.e., screening) 
● Matching (e.g., age, sex) 
● Exclusion criteria 
Cases and controls 
● Age 
● Biological sex or gender 
● Height 
● Weight 
● Body mass index 
● Ancestry 
● Socioeconomic status 
Cases 
● Age of onset 
● Duration of illness 
Body composition Menstrual status 
● Fat mass 
● Fat-free mass 
● Bone mineral content & density 
● Ideally: muscle mass 
Cases 
● Dysmenorrhea or amenorrhea 
● Duration of amenorrhea 
● Age of menarche 
 38 
 
● Measurement method: 
MRI, DXA, or BIA 
● Physical activity  
(ideally accelerometer data) 
● If menstruating, stage or day of cycle 
Controls 
● Stage or day of the menstrual cycle 
(e.g., follicular phase) 
Blood sampling Substances 
● Blood sample type 
Whole blood, serum, plasma 
● Fasting state 
● Fasting period 
● The time point of blood sampling 
● Pre-analytics 
● Storage 
● Storage duration 
Dose and duration of 
● Contraceptives 
● Supplements & vitamins 
● Medication 
○ Prescription 
○ Over the counter 
● Laxatives 
● Illicit drugs 
● Alcohol consumption 
● Smoking behaviour 
BIA, bioelectrical impedance analysis, DXA, dual-energy X-ray absorptiometry, MRI, 
magnetic resonance imaging 
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